Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe - The HEALTH model

Value in Health

Volumn 12, Issue 6, 2009, Pages 857-871

  Schwander, Björn ^a   Gradl, Birgit ^b   Zöllner, York ^b   Lindgren, Peter ^c   Diener, Hans Christoph ^d   Lüders, Stephan ^e   Schrader, Joachim ^e   Villar, Fernando Antoñanzas ^f   Greiner, Wolfgang ^g   Jönsson, Bengt ^h  

^a Analytica International   (Germany)

^b Solvay Pharmaceuticals Marketing and Licensing AG   (Switzerland)

^c i3 Innovus   (Sweden)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e ST JOSEFS HOSPITAL   (Germany)

^f UNIVERSITY OF LA RIOJA   (Spain)

^g BIELEFELD UNIVERSITY   (Germany)

^h STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

Cost utility; Enalapril; Eprosartan; Nitrendipine

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; GENERIC DRUG; NITRENDIPINE; RAMIPRIL; TELMISARTAN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; COST UTILITY ANALYSIS; DRUG COST; EUROPE; FEMALE; HEALTH ECONOMICS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; RISK REDUCTION; STROKE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ACRYLATES; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; ENALAPRIL; EUROPE; GEOGRAPHY; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; MONTE CARLO METHOD; NITRENDIPINE; PRIMARY PREVENTION; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SECONDARY PREVENTION; STROKE; THIOPHENES;

EID: 67651238846     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00507.x     Document Type: Article

References (114)

1. Elliott P, Law M, Lawes C, et al. Quantifying Selected Major Risks To Health - High Blood Pressure, Murray C, Lopez A, The World Health Report 2002 - Reducing Risks, Promoting Healthy Life. Geneva, Switzerland : World Health Organization, 2002.
2. Mancia G, De Backer G, Dominiczak A, et al. ESH-ESC Guidelines for the management of arterial Hypertension: the task force for the management of arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press 2007 16 : 135 232.
3. Pearce KA, Furberg CD, Rushing J. Does antihypertensive treatment of the elderly prevent cardiovascular events or prolong life? A meta-analysis of hypertension treatment trials. Arch Fam Med 1995 4 : 943 9.
4. Gueyffier F, Boutitie F, Boissel JP, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med 1997 126 : 761 7.
5. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997 277 : 739 45.
6. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 2003 34 : 2741 8.
7. Turnbull F, Neal B, Algert C, et al. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003 362 : 1527 35.
8. Cheung BM, Cheung GT, Lauder IJ, et al. Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension. J Hum Hypertens 2006 20 : 37 43.
9. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003 289 : 2534 44.
10. Sega R. Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group. Blood Press 1999 8 : 114 21.
11. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003 21 : 1055 76.
12. Wang JG, Staessen JA. Benefits of antihypertensive pharmacologic therapy and blood pressure reduction in outcome trials. J Clin Hypertens 2003 5 : 66 75.
13. Lawes CM, Rodgers A, Bennett DA, et al. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003 21 : 707 16.
14. Lawes CM, Bennett DA, Feigin VL, et al. Blood pressure and stroke: an overview of published reviews. Stroke 2004 35 : 776 85.
15. Chalmers J, MacMahon S, Bousser M-G, et al. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001 358 : 1033 41.
16. Schrader J, Lüders S, Kulschewski A, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005 36 : 1218 26.
17. Schmeider RE. Mechanisms for the clinical benefits of angiotensin receptor II blockers. Am J Hypertens 2005 18 : 720 30.
18. Hunink MG, Bult JR, de Vries J, et al. Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method. Med Decis Making 1998 18 : 337 46.
19. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000 139 : 272 81.
20. Wolf PA, D'Agostino RB, Belanger AJ, et al. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991 22 : 312 18.
21. Sacco RL, Wolf PA, Kannel WB, et al. Survival and recurrence following stroke. The Framingham study. Stroke 1982 13 : 290 5.
22. Cupples LA, D'Agostino RB, Kiely D, Survival following initial cardiovascular events - The Framingham Study Section 35. In : Kannel WB, Wolf PA, Garrison RJ, eds. The Framingham Study - An Epidemiological Investigation of Cardiovascular Disease. Bethesda, MD : US National Institutes of Health, 1988.
23. World Health Organization. Life tables for WHO member states. 2007. Available from: http://www.who.int/whosis/database/life-tables/life-tables.cfm [Accessed November 19, 2007].
24. Hardie K, Hankey GJ, Jamrozik K, et al. Ten-year survival after first-ever stroke in the Perth community stroke study. Stroke 2003 34 : 1842 6.
25. Kolominsky-Rabas PL, Weber M, Gefeller O, et al. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke 2001 32 : 2735 40.
26. L'Ecuyer P, Zauberman G, Ariely D, et al. Good parameters and implementations for combined multiple recursive random number generators. Oper Res 1999 47 : 159 64.
27. Conlin PR, Gerth WC, Fox J, et al. Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clin Ther 2001 23 : 1999 2010.
28. Sappok T, Faulstich A, Stuckert E, et al. Compliance with secondary prevention of ischemic stroke: a prospective evaluation. Stroke 2001 32 : 1884 9.
29. Annemans L, Crott R, Degraeve D, et al. Recommended structure for reporting economic evaluation on pharmaceuticals in Belgium. Pharm World Sci 2002 24 : 5 7.
30. Schulenburg J-M, Greiner W, Jost F, et al. German recommendations on health economic evaluation - third and updated version of the Hanover Consensus. Gesundheitsökon Qualitätsmanage 2007 12 : 285 90.
31. Department of pharmacoeconomics of the Norwegian Medicines Agency. Norwegian guidelines for pharmacoeconomic analysis in connection with applications for reimbursement. 2005. Available from: http://www. legemiddelverket.no/templates/InterPage-25644.aspx [Accessed December 10, 2007].
32. Rovira J, Antonanzas F. Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation. Pharmacoeconomics 1995 8 : 245 52.
33. Swedish Pharmaceutical Benefits Board. General guidelines for economic evaluations - Sweden. 2003. Available from: http://www.lfn.se/upload/English/ ENG-lfnar2003-eng.pdf [Accessed November 20, 2007].
34. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal: section 5: Clinical and cost effectiveness and NHS impact. 2004. Available from: http://www.nice.org.uk/niceMedia/pdf/TAP- Methods.pdf [Accessed December 12, 2007].
35. Evans C, Tavakoli M, Crawford B. Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal. Health Care Manag Sci 2004 7 : 43 9.
36. Socialstyrelsen. The Swedish National Board of Health and Welfare's guidelines for cardiac care - support for decisions in setting priorities. 2004. Available from: http://www.sos.se/ [Accessed May 3, 2008].
37. Persson U, Hjelmgren J. Hälso- och sjukvården behöver kunskap om hur befolkningen värderar hälsan. Läkartidningen 2003 100 : 3436 7.
38. Lundin D. Kostnadseffektivitet som kriterium för subvention av läkemedel - en bra idé? ekonomiskdebatt 2004 34 : 32 40.
39. Bastian H, Bender R, Kaiser T, et al. IQWiG Methoden Version 1.0. Cologne, Germany : Institute for Quality and Efficiency in Health Care, 2005. Available from: http://www.iqwig.de/download/Methoden-IQWiG-V-1-0.pdf [Accessed December 13, 2007].
40. Bellach BM The 1998 Federal Health Survey. Experiences, results, perspectives Gesundheitswesen 1999 61 : Spec No : S55 6.
41. Hallan H, Romundstad S, Kvenild K, et al. Microalbuminuria in diabetic and hypertensive patients and the general population - consequences of various diagnostic criteria - the Nord-Trondelag Health Study (HUNT). Scand J Urol Nephrol 2003 37 : 151 8.
42. Kvenild K, Romundstad S, Midthjell K, et al. Microalbuminuria in treated hypertensives: only a mirror image of cardiovascular risk? The HUNT Study, Norway. Scand J Prim Health Care 2006 24 : 145 53.
43. Kuch B, Schunkert H, Muscholl M, et al. Distribution, determinants and reference values of left ventricular parameters in the general population - results of the MONICA/KORA echocardiography studies Gesundheitswesen 2005 67 (Suppl. 1 S68 73.
44. Cederholm J, Nilsson PM, Anderberg CP, et al. Blood pressure and other cardiovascular risk factors among treated hypertensives in Swedish primary health care. Scand J Prim Health Care 2002 20 : 224 9.
45. Lindblad U, Rastam L, Ryden L, et al. Control of blood pressure and risk of first acute myocardial infarction: skaraborg hypertension project. BMJ 1994 308 : 681 6.
46. Nilsson P, Andersson DK, Andersson PE, et al. Cardiovascular risk factors in treated hypertensives - a nation-wide, cross-sectional study in Sweden. J Intern Med 1993 233 : 239 45.
47. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006 27 : 949 53.
48. Ostgren CJ, Merlo J, Rastam L, et al. Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. Diabetes Obes Metab 2004 6 : 367 74.
49. Thomas F, Renaud F, Benefice E, et al. International variability of ages at menarche and menopause: patterns and main determinants. Hum Biol 2001 73 : 271 90.
50. Jacobsen BK, Heuch I, Kvale G. Age at natural menopause and stroke mortality: cohort study with 3561 stroke deaths during 37-year follow-up. Stroke 2004 35 : 1548 51.
51. Lidfeldt J, Nyberg P, Nerbrand C, et al. Socio-demographic and psychosocial factors are associated with features of the metabolic syndrome. The Women's Health in the Lund Area (WHILA) study. Diabetes Obes Metab 2003 5 : 106 12.
52. Lozano JV, Redon J, Cea-Calvo L, et al. Risk assessment for a first stroke in Spanish hypertensive population in primary care. The ERIC-HTA study Med Clin (Barc) 2005 125 : 247 51.
53. Bog-Hansen E, Lindblad U, Bengtsson K, et al. Risk factor clustering in patients with hypertension and non-insulin-dependent diabetes mellitus. The Skaraborg Hypertension Project. J Intern Med 1998 243 : 223 32.
54. National Centre for Social Research, Department of Epidemiology and Public Health at the Royal Free and University College Medical School. Commissioned by Department of Health, England health survey 2003. UK data archive, 2004.
55. Ostgren CJ, Lindblad U, Melander A, et al. Survival in patients with type 2 diabetes in a Swedish community: skaraborg hypertension and diabetes project. Diabetes Care 2002 25 : 1297 302.
56. Ceinos AM, Acosta EE, Martin PC, et al. Risk factors related to osteoporosis and age of onset of menopause in the general population Aten Primaria 1999 24 : 140 4.
57. Rodstrom K, Bengtsson C, Milsom I, et al. Evidence for a secular trend in menopausal age: a population study of women in Gothenburg. Menopause 2003 10 : 538 43.
58. Tuesca-Molina R, Guallar-Castillon P, Banegas-Banegas JR, et al. Factors associated with the control of hypertension among older Spaniards, over 60 years of age Rev Esp Salud Publica 2006 80 : 233 42.
59. Thomas F, Renaud F, Benefice E, et al. International variability of ages at menarche and menopause: patterns and main determinants. Hum Biol 2001 73 : 271 90.
60. Burström K, Johannesson M, Diderichsen F. Health-related quality of life by disease and socio-economic group in the general population in Sweden. Health Policy 2001 55 : 51 69.
61. Bell CM, Chapman RH, Stone PW, et al. An off-the-shelf help list: a comprehensive catalog of preference scores from published cost-utility analyses. Med Decis Making 2001 21 : 288 94.
62. FPS Economy, SMEs, Self-employed and Energy. Healthcare cost index Belgium (Indice santé). 2007. Available from: http://economie.fgov.be/ [Accessed November 29, 2007].
63. Federal Statistical Office. Healthcare cost index Germany. 2007. Available from: http://www.destatis.de [Accessed November 29, 2007].
64. Statistics Norway. Healthcare cost index Norway. 2007. Available from: http://www.ssb.no [Accessed November 29, 2007].
65. The National Statistics Institute. Healthcare cost index Spain. 2007. Available from: http://www.ine.es [Accessed November 29, 2007].
66. Statistics Sweden. Healthcare cost index Sweden. 2007. Available from: http://www.scb.se/ [Accessed November 29, 2007].
67. The Office for National Statistics. Healthcare cost index UK. 2007. Available from: http://www.statistics.gov.uk [Accessed November 29, 2007].
68. Fjaertoft H, Indredavik B Cost-estimates for stroke Tidsskr Nor Laegeforen 2007 127 : 744 7.
69. The European Central Bank. Euro foreign exchange reference rates for Norway, Sweden and the UK. 2007. Available from: http://www.ecb.de/stats/ exchange/eurofxref/html/index.en.html [Accessed November 29, 2007].
70. Institut national d'assurance maladie-invalidité (INAMI). Drug costs Belgium: Liste des spécialités pharmaceutiques remboursables. 2007. Available from: http://www.inami.fgov.be [Accessed November 29, 2007].
71. Rote Liste® Service GmbH Frankfurt/Main. Drug costs Germany: ROTE LISTE® - Arzneimittelsverzeichnis für Deutschland (online). 2007. Available from: http://www.rote-liste.de [Accessed November 29, 2007].
72. Norwegian Medicines Agency (NoMA). Drug costs Norway: Prisdatabase (PIA). 2007. Available from: http://www.legemiddelverket.no [Accessed November 29, 2007].
73. IMS Health. Drug costs Spain: Spanish IMS drug cost database. 2007. Available from: http://www.imshealth.com [Accessed November 20, 2007].
74. Pharmaceutical Benefits Board (LFN). Drug costs Sweden: Sök priser på läkemedel. 2007. Available from: http://www.lfn.se [Accessed November 29, 2007].
75. National Health Service England and Wales. Drug costs UK: the NHS Electronic Drug Tariff. 2007. Available from: http://www.ppa.org.uk [Accessed November 29, 2007].
76. Staessen JA, Den Hond E, Celis H, et al. Antihypertensive treatment based on blood pressure measurement at home or in the physician's office: a randomized controlled trial. JAMA 2004 291 : 955 64.
77. Association of Statutory Health Insurance Physicians. German physician fee schedule (EBM 2000 plus), version of the fourth quarter 2007. 2007. Available from: http://www.kbv.de [Accessed November 29, 2007].
78. Johannesson M, Meltzer D, O'Conor RM. Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension. Med Decis Making 1997 17 : 382 9.
79. Badia X, Bueno H, Gonzalez J Jr., et al. Short-and long-term cost-effectiveness analysis of adding clopidogrel to standard therapy in acute coronary syndrome patients in Spain Rev Esp Cardiol 2005 58 : 1385 95.
80. UK Department of Health. NHS reference costs. 2006. Available from: http://www.dh.gov.uk [Accessed November 29, 2007].
81. Levy E, Gabriel S, Dinet J. The comparative medical costs of atherothrombotic disease in European countries. Pharmacoeconomics 2003 21 : 651 9.
82. Muls E, Van Ganse E, Closon MC. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model. Atherosclerosis 1998 137 (Suppl. S111 16.
83. Schoenen J, Gianni F, Schretlen L, et al. Cost estimates of brain disorders in Belgium. Acta Neurol Belg 2006 106 : 208 14.
84. Kolominsky-Rabas PL, Heuschmann PU, Marschall D, et al. Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project. Stroke 2006 37 : 1179 83.
85. Mullins CD, Sikirica M, Seneviratne V, et al. Comparisons of hypertension-related costs from multinational clinical studies. Pharmacoeconomics 2004 22 : 1001 14.
86. Ray JA, Valentine WJ, Secnik K, et al. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Curr Med Res Opin 2005 21 : 1617 29.
87. Rossnagel K, Nolte CH, Muller-Nordhorn J, et al. Medical resource use and costs of health care after acute stroke in Germany. Eur J Neurol 2005 12 : 862 8.
88. Carod-Artal FJ, Egido-Navarro JA, Gonzalez-Gutierrez JL, et al. Direct cost of cerebrovascular disease during the first year of follow-up Rev Neurol 1999 28 : 1123 30.
89. Andersson A, Levin LA, Oberg B, et al. Health care and social welfare costs in home-based and hospital-based rehabilitation after stroke. Scand J Caring Sci 2002 16 : 386 92.
90. Ghatnekar O, Persson U, Glader EL, et al. Cost of stroke in Sweden: an incidence estimate. Int J Technol Assess Health Care 2004 20 : 375 80.
91. Caro JJ, Huybrechts KF. Stroke treatment economic model (STEM): predicting long-term costs from functional status. Stroke 1999 30 : 2574 9.
92. Youman P, Wilson K, Harraf F, et al. The economic burden of stroke in the United Kingdom. Pharmacoeconomics 2003 21 (Suppl. 1 S43 50.
93. Zethraeus N, Molin T, Henriksson P, et al. Costs of coronary heart disease and stroke: the case of Sweden. J Intern Med 1999 246 : 151 9.
94. Finnern HW, Sykes DP. The hospital cost of vertebral fractures in the EU: estimates using national datasets (includes the cost per hospital day in Belgium). Osteoporos Int 2003 14 : 429 36.
95. Balestat G, Canaud MC, Lafortune G, et al. OECD Health Data 2006: Mean length of stay for TIA in Belgium. Paris : Organisation for Economic Co-operation, 2006.
96. Dodel RC, Haacke C, Zamzow K, et al. Resource utilization and costs of stroke unit care in Germany. Value Health 2004 7 : 144 52.
97. Institut für das Entgeltsystem im Krankenhaus (Institute for the Hospital Renumeration System). G-DRG case weights 2007. 2007. Available from: http://www.g-drg.de/ [Accessed November 29, 2007].
98. Norwegian Directorate for Health and Social Affairs (Sosial-og helsedirektoratet). Hospital funding 2007 (Innsatsstyrt finansiering 2007). 2007. Available from: http://www.shdir.no/ [Accessed August 27, 2007].
99. Navarro Espigares JL, González López JM, Hernandez Torres L, et al. Cost-Effectiveness Analysis of Ambulatory Treatment Based on Eco-Doppler Examination for Patients with Transient Ischemic Attack. The 115th annual meeting of the American Public Health Association, 2007.
100. Swedish National Board for Health and Welfare (Socialstyrelsen). Swedish NordDRG weights for 2007. 2007. Available from: http://www.socialstyrelsen.se [Accessed August 27, 2007].
101. Stockholm Country Council. Estimated DRG cases and estimated costs per DRG point of hospitals within the Stockholm region. 2007. Available from: http://www.sll.se/ [Accessed August 27, 2007].
102. Allender S, Scarborough P, Boxer A, et al., Economic Costs, Coronary Heart Disease Statistics. London : The British Heart Foundation, 2007.
103. Annemans L, Backer W, Rompay W, et al. Evaluation of the costs of coronary heart disease in Belgium. Value Health 1998 1 : 33.
104. Klever-Deichert G, Hinzpeter B, Hunsche E, et al. Costs of coronary heart diseases over the remaining life time in coronary heart disease cases - an analysis of the current status of coronary heart disease cases in Germany from the social perspective Z Kardiol 1999 88 : 991 1000.
105. Taylor MJ, Scuffham PA, McCollam PL, et al. Acute coronary syndromes in Europe: 1-year costs and outcomes. Curr Med Res Opin 2007 23 : 495 503.
106. Clarke P, Gray A, Legood R, et al. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003 20 : 442 50.
107. Koster I, Hauner H, von Ferber L Heterogeneity of costs of diabetic patients: the Cost of Diabetes Mellitus Study Dtsch Med Wochenschr 2006 131 : 804 10.
108. Gomez-Gerique JA, Casciano R, Stern L, et al. A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain. Eur J Health Econ 2004 5 : 278 84.
109. Jönsson B. Measurement of health outcome and associated costs in cardiovascular disease. Eur Heart J 1996 17 (Suppl. A S2 7.
110. Levine B. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension. Curr Med Res Opin 2001 17 : 8 17.
111. Neutel JM. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients. Curr Med Res Opin 2008 24 : 2389 401.
112. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007 29 : 563 80.
113. Mann JFE, Schmeider RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet 2008 372 : 547 3.
114. National Collaborating Centre for Chronic Conditions. Hypertension: Management in Adults in Primary Care: Pharmacological Update. London : Royal College of Physicians, 2006.